Data availability
Data are available as Electronic Supplementary Material from reference [1].
References
Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients. Clin Pharmacokinet. 2019;58:827–33. https://doi.org/10.1007/s40262-019-00747-3.
Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, et al. Why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one. Clin Pharmacokinet. 2020;59(1):1–5. https://doi.org/10.1007/s40262-019-00812-x.
Krebs-Brown A, Munafo A, Gaikwad S, Urgatz B, Castello-Bridoux C. Comment on: “Why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one?”. Clin Pharmacokinet. 2020;59:265–7. https://doi.org/10.1007/s40262-019-00847-0.
Nicolas P. Comment on: “Why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one?”. Clin Pharmacokinet. 2020;59:273–5. https://doi.org/10.1007/s40262-019-00849-y.
Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95–105% specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin. 2017;33:169–74. https://doi.org/10.1080/03007995.2016.1246434.
L'ansm. L'ansm publie les résultats des enquêtes nationales de pharmacovigilance sur les spécialités à base de lévothyroxine—communiqué. 2018. https://ansm.sante.fr/S-informer/Communiques-Communiques-Points-presse/L-ANSM-publie-les-resultats-des-enquetes-nationales-de-pharmacovigilance-sur-les-specialites-a-base-de-levothyroxine-Communique. Accessed 25 Mar 2020.
Chow SC. Bioavailability and bioequivalence in drug development. Wiley Interdiscip Rev Comput Stat. 2014;6:304–12. https://doi.org/10.1002/wics.1310.
Krehan A, Dittmar M, Hoppen A, Lichtwald K, Kahaly GJ. Randomized, double-blind crossover study of bioavailability of levothyroxine. Med Klin (Munich). 2002;97:522–7. https://doi.org/10.1007/s00063-002-1190-4.
Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options. Drugs Context. 2019;8:212597. https://doi.org/10.7573/dic.212597.
Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002;87:1068–72. https://doi.org/10.1210/jcem.87.3.8165.
Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Functional and symptomatic individuality in the response to levothyroxine treatment. Front Endocrinol (Lausanne). 2019;26(10):664. https://doi.org/10.3389/fendo.2019.00664.
Molenaar PCM, Campbell CG. The new person-specific paradigm in psychology. Curr Dir Psychol Sci. 2009;18:112–7. https://doi.org/10.1111/j.1467-8721.2009.01619.x.
Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Author information
Authors and Affiliations
Contributions
RH drafted the manuscript and JEM, RL and JWD contributed additional ideas and text to the final jointly approved article.
Corresponding author
Ethics declarations
Conflict of interest
Johannes W. Dietrich is the co-owner of the intellectual property rights for the patent “System and Method for Deriving Parameters for Homeostatic Feedback Control of an Individual” (Singapore Institute for Clinical Sciences, Biomedical Sciences Institutes, Application Number 201208940-5, WIPO number WO/2014/088516). Rudolf Hoermann, John E.M. Midgley and Rolf Larisch have no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.
Rights and permissions
About this article
Cite this article
Hoermann, R., Midgley, J.E.M., Larisch, R. et al. Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”. Clin Pharmacokinet 59, 655–657 (2020). https://doi.org/10.1007/s40262-020-00887-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-020-00887-x